Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T39992 |
FGFR1 inhibitor-2
FGFR1 inhibitor-2 |
||
FGFR1 inhibitor-2 (with an IC50 of 4.55 μM in MDA-MB-231 cells) is a potent inhibitor of FGFR1. It is specifically useful for studying metastatic triple-negative breast cancer. | |||
T1975 |
Infigratinib
BGJ-398,NVP-BGJ398 |
Apoptosis; FGFR | Angiogenesis; Apoptosis; Tyrosine Kinase/Adaptors |
Infigratinib (NVP-BGJ398) 是一种 FGFR 家族抑制剂,抑制 FGFR1,FGFR2,FGFR3和 FGFR4的 IC50分别为 0.9 nM,1.4 nM,1 nM,60 nM。 | |||
T16781 |
Rogaratinib
BAY1163877 |
FGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Rogaratinib (BAY1163877) 选择性抑制成纤维细胞生长因子受体。 | |||
T4425 |
JK-P3
|
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
JK-P3 是广谱 VEGFR2抑制剂。它能够抑制 VEGF-A 刺激的 VEGFR2 激活和细胞内信号转导,也可阻碍内皮单层细胞迁移和血管生成,影响成纤维细胞生长因子受体激酶在体外的活性。它具有抗血管生成的作用。 | |||
T2064 |
Semaxinib
司马沙尼,SU5416 |
VEGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
Semaxinib (SU5416) 是一种选择性的 VEGFR(Flk-1/KDR) 抑制剂,其 IC50=1.23 μM。 | |||
T62653 |
FGFR-IN-2
|
||
FGFR-IN-2 (compound 1) 是一种有效的 FGFR 抑制剂,能够作用于 FGFR1 (IC50: 7.3 nM)、FGFR2 (IC50: 4.3 nM)、FGFR3 (IC50: 7.6 nM) 和 FGFR4 (IC50: 11 nM)。FGFR-IN-2 具有潜力进行癌症研究。 | |||
T79880 |
FGFR4-IN-16
|
FGFR | Angiogenesis; Tyrosine Kinase/Adaptors |
FGFR4-IN-16 (CY-15-2)为FGFR-4选择性共价抑制剂,适用于癌症研究领域。 | |||
T71944 |
FGF/PDGF/VEGF RTK Inhibitor
|
||
FGF/PDGF/VEGF RTK Inhibitor is a potent, reversible, atp-competitive inhibitor against pdgfrβ, fgfr-1, and vegfr-2 (ic50 = 20, 90, and 240 nm, respectively) and effectively suppresses vegf-stimulated proliferation of hmvecs (ec50 = 420 nm). | |||
T63967 |
Multi-kinase-IN-2
|
||
Multi-kinase-IN-2 是口服具有活力的血管激酶 (angiokinase) 抑制剂。Multi-kinase-IN-2 能够显著抑制血管激酶的活性,如 VEGFR-1/2/3、PDGFRα/β、FGFR-1、LYN 和 c-KIT 激酶。Multi-kinase-IN-2 能够明显减弱 AKT 和 ERK 蛋白的磷酸化,并可诱导细胞凋亡 (apoptosis),具有抗癌作用。 |